Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $25.59 to $25.59
• 50-Day Range: $25.55 to $25.59
• 52-Week Range: $9.90 to $25.61
• Volume: 600 shs
• Average Volume: 1.29 million shs
• Market Capitalization: $2.21 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.24
• Consensus Rating: Hold

Deciphera Pharmaceuticals Stock Analysis - MarketRank™

Deciphera Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat, and ranked 892nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Deciphera Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Deciphera Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.15) to ($1.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Deciphera Pharmaceuticals is -11.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Deciphera Pharmaceuticals has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DCPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Deciphera Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Deciphera Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.6 / 5
• Environmental Score: -1.96

Short Interest

There is no current short interest data available for DCPH.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.67% of the stock of Deciphera Pharmaceuticals is held by insiders.

Percentage Held by Institutions

70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DCPH Stock Analysis - Frequently Asked Questions

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, February, 6th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. The firm's revenue for the quarter was up 32.9% on a year-over-year basis.

When did Deciphera Pharmaceuticals IPO?

Deciphera Pharmaceuticals (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/06/2024
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DCPH
• CUSIP: N/A
• CIK: 1654151
• Web: www.deciphera.com
• Phone: (781) 209-6400
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.24
• High Stock Price Target: $26.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: -9.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-194,940,000.00
• Net Margins: -108.86%
• Pretax Margin: -108.62%
• Return on Equity: -52.42%
• Return on Assets: -40.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.19
• Quick Ratio: 3.94

Sales & Book Value

• Annual Sales: $174.91 million
• Price / Sales: 12.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.38 per share
• Price / Book: 5.84

Miscellaneous

• Outstanding Shares: 86,476,000
• Free Float: 82,438,000
• Market Cap: $2.21 billion
• Optionable: Optionable
• Beta: 0.19